OSSIO Closes Series C Financing of $38.5 Million

OSSIO has closed $38.5 million in Series C financing. The additional funding will support further adoption of OSSIOfiber® Intelligent Bone Regeneration Technology with new product development, sales force expansion, patient outreach and medical education.

All OSSIO implants are made with OSSIOfiber Intelligent Bone Regeneration Technology, a fixation material that offers an alternative to permanent metal hardware, conventional resorbable and allograft implants. Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, the technology features bio-integrative material properties that provide surgeons with a more biologically friendly way to restore patient stability and mobility while leaving nothing permanent behind.

Designed for rapid bone in-growth, regeneration and replacement, OSSIOfiber Intelligent Bone Regeneration Technology is a first-of-its-kind implant material that is reportedly stronger than cortical bone. OSSIOfiber is engineered to provide the strength required for functional fixation and allows for full integration into the native anatomy without adverse biological response. OSSIOfiber implants utilize existing reimbursement and surgical techniques.

More than 10,000 OSSIOfiber implants have already been used in orthopedic surgeries since their commercial introduction in 2019.

Source: OSSIO